Iterum Therapeutics plc
DelistedCIK 1659323fmd_1WX2DY9T7FH9MEJV08YK68YVQ3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2025, 35 periods
Latest annual · FY2021
Millions- Total revenues
- 0
- Operating income
- (19)
- Net income
- (25)
- Free cash flow
- (27)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 0
- Operating income
- (8)
- Net income
- (9)
- Free cash flow
- (7)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Iterum Therapeutics plc financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$18.7 million | -$47.5 million | 10-K 2025-02-07 · proof | |
| Net income | -$24.8 million | -$38.4 million | 10-K 2025-02-07 · proof | |
| Cash from operating activities | -$26.8 million | -$39.3 million | 10-K 2025-02-07 · proof | |
| Free cash flow | -$26.8 million | -$39.3 million | 10-K 2025-02-07 · proof | |
| Total assets | $44.6 million | $26.3 million | +69.8% | 10-K 2025-02-07 · proof |
| Total liabilities | $48.7 million | $32.7 million | +49% | 10-K 2025-02-07 · proof |
| Cash and cash equivalents | $24.1 million | $6.1 million | +297.4% | 10-K 2025-02-07 · proof |
- What was Iterum Therapeutics plc's operating income in fiscal 2024?
- Iterum Therapeutics plc reported operating income of -$18.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$47.5 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What was Iterum Therapeutics plc's net income in fiscal 2024?
- Iterum Therapeutics plc reported net income of -$24.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$38.4 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What was Iterum Therapeutics plc's cash from operating activities in fiscal 2024?
- Iterum Therapeutics plc reported cash from operating activities of -$26.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$39.3 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What was Iterum Therapeutics plc's free cash flow in fiscal 2024?
- Iterum Therapeutics plc reported free cash flow of -$26.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$39.3 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What are Iterum Therapeutics plc's total assets?
- As of Dec 31, 2024, Iterum Therapeutics plc reported total assets of $44.6 million, against $26.3 million a year earlier (+69.8%). Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What are Iterum Therapeutics plc's total liabilities?
- As of Dec 31, 2024, Iterum Therapeutics plc reported total liabilities of $48.7 million, against $32.7 million a year earlier (+49%). Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
- What are Iterum Therapeutics plc's cash and cash equivalents?
- As of Dec 31, 2024, Iterum Therapeutics plc reported cash and cash equivalents of $24.1 million, against $6.1 million a year earlier (+297.4%). Source: the 10-K filed with the SEC on Feb 7, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1659323&period_type=annual&limit=5"Information only, not investment advice.